Medicover Integrated Clinical Services (MICS) has collaborated with ARUP Laboratories to bring the AAV5 DetectCDx™ companion diagnostic test to patients in the European Union.
The test was developed by ARUP Laboratories in close collaboration with Biomarin Pharmaceutical Inc., to identify adult patients with severe haemophilia A who are eligible for treatment with ROCTAVIAN™. MICS is proud of its role in making this companion diagnostic test and revolutionary gene therapy accessible to patients in the European Union. We look forward to bringing more new companion diagnostic tests and therapies to the EU in collaboration with our international partners.
Medicover Integrated Clinical Services (MICS) is a strategic business organization of Medicover, a leading international healthcare and diagnostic services provider headquartered in Sweden and listed on Nasdaq Stockholm. The overarching objective of MICS is to support the development and commercialization of innovative therapies and medicines through the network of Medicover diagnostic and healthcare services in Europe and India, and its global network of partners.
MICS focuses on clinical applications and clients from pharmaceuticals, diagnostics, biopharma, biotech, medtech and contract research organisations (CROs) in this exciting and growing healthcare sector. MICS has been providing bespoke services to clients and their patients for 25 years, making strategic use of Medicover assets, including laboratories with state-of-the-art diagnostic equipment, medical clinics and hospitals, and the vast expertise and enthusiasm of our team of over 200 professionals.
